Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

514
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
514
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

727
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
727
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.3K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

478
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
478
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic accuracy of photon-counting CT for in-stent restenosis: A preliminary meta-analysis.

Journal of cardiovascular computed tomography·2026
Same author

The gut-heart axis in cardio-oncology.

Cardiovascular research·2026
Same author

Quantitative rapid image-based method for coronary artery blood flow and wall shear stress extraction.

Frontiers in bioengineering and biotechnology·2026
Same author

The asialoglycoprotein receptor 1 (ASGR1): emerging new roles in health and disease.

Biomarker research·2026
Same author

SUpporting Mothers Milk Intervention Trial (SUMMIT) - a randomised controlled trial comparing different doses of domperidone for treating lactation insufficiency in mothers of preterm infants - study protocol.

International breastfeeding journal·2026
Same author

Syndecan-1, endocan and non-culprit coronary plaque composition following non-ST elevation myocardial infarction.

International journal of cardiology. Heart & vasculature·2026

Related Experiment Video

Updated: Mar 19, 2026

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.5K

Cellular Therapy for Heart Failure.

Peter J Psaltis1, Nisha Schwarz, Deborah Toledo-Flores

  • 1Co-Director of Vascular Research Centre, Heart Health Theme, South Australian Health and Medical Research Institute, North Terrace, Adelaide, South Australia, Australia 5000. peter.psaltis@sahmri.com.

Current Cardiology Reviews
|June 10, 2016
PubMed
Summary
This summary is machine-generated.

Cellular transplantation shows promise for heart failure (HF) by facilitating cardiac repair through stem cell paracrine effects. Further research is needed to overcome challenges and optimize cell therapy for managing HF.

More Related Videos

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.5K
Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

11.0K

Related Experiment Videos

Last Updated: Mar 19, 2026

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.5K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.5K
Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

11.0K

Area of Science:

  • Cardiology
  • Regenerative Medicine
  • Stem Cell Biology

Background:

  • Heart failure (HF) pathogenesis involves complex myocardial changes, with conventional treatments inadequately addressing cardiomyocyte loss.
  • Cellular transplantation has evolved over two decades to address HF, utilizing various cell types and delivery routes.

Purpose of the Study:

  • To review preclinical and clinical evidence of stem cell therapy for cardiomyopathy and HF.
  • To outline lessons learned and identify challenges for realizing cell therapy's full potential in HF management.

Main Methods:

  • Review of preclinical models and early-phase human studies on cell transplantation for HF.
  • Analysis of stem cell types, delivery routes, and observed therapeutic effects.

Main Results:

  • Preclinical studies show pleiotropic benefits of cell transplantation, including improved myocardial remodeling, function, perfusion, and reduced fibrosis/inflammation.
  • Observed benefits are largely attributed to the paracrine effects of transplanted stem cells promoting endogenous repair.
  • Early human studies show modest and inconsistent, yet promising, results.

Conclusions:

  • Cellular transplantation, particularly via stem cell paracrine mechanisms, offers a promising avenue for HF treatment.
  • Key challenges and research questions remain to optimize cell therapy and integrate it into the HF management armamentarium.